Highlights

  • The US Department of Commerce has agreed to delay Section 232 tariffs for three years to support complete domestic production.
  • AstraZeneca intends to invest USD 50 billion in R&D and US manufacturing, with a target of USD 80 billion in revenue by 2030.
  • The company expands US operations with new manufacturing and R&D sites, supporting over 100,000 American jobs.

AstraZeneca (LSE:AZN) is a global, research-driven biopharmaceutical company dedicated to the discovery, development, and marketing of innovative prescription medicines across Oncology, Rare Diseases, and BioPharmaceuticals. Headquartered in Cambridge, UK, the company’s therapies improve the lives of patients in more than 125 countries.

AstraZeneca Reaches Agreement with US Government

On 13 October 2025, the company announced a contract with the US Government to decrease the cost of prescription medicines for American patients while supporting the country’s biopharmaceutical innovation. The agreement follows a letter from President Donald J. Trump on 31 July, outlining four key requests to lower medicine costs. AstraZeneca confirmed that it voluntarily met all requests set forth by the administration.

Direct-to-Consumer Discounts and TrumpRx.gov Participation

Under the agreement, AZN will offer DTC sales for patients with chronic disease prescriptions, providing discounts of up to 80% off list prices. The company will also participate in the TrumpRx.gov direct purchasing platform, which allows patients to buy medicines at reduced cash prices.

Onshoring Manufacturing and Investment Plans

The company finalized a deal with the US Department of Commerce to defer Section 232 tariffs for a period of three years. This will support full onshoring of medicine manufacturing, ensuring that all medicines sold in the US are produced domestically.

The company intends to make investment of USD 50 billion in R&D and US manufacturing over the next five years. This investment aims to deliver USD 80bn in total revenue by 2030, with half expected from the US market.

Pascal Soriot, CEO of AstraZeneca, stated:
"Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today's agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America's pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation."

Expanding US Presence

The agreement aligns with AZN’s broader US operations, which include 19 R&D, manufacturing, and commercial sites. In 2025 alone, AstraZeneca generated approximately USD 20bn of value for the American economy.

Recently, AZN broke ground on its largest manufacturing facility in Virginia to support its weight management and metabolic portfolio and antibody drug conjugate cancer pipeline. A manufacturing facility in Coppell, Texas, will open next week, while a cell therapy site in Rockville, Maryland, is planned for early next year. A second R&D centre in Cambridge, Massachusetts, is set to open in late 2026.

Share Performance of AZN

On Nasdaq, the shares were trading at USD 84.53 per stock, down approximately 0.60% from its previous close of USD 85.04.